Skip to main content

Table 4 Selected SBRT series in patients with primary and secondary liver tumors

From: Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease

Author, Year
Study-Type
n (patients)
n (lesions)
n (primary LT)
n (metastases)
GTV volume (median/range)a 1 yr-LC (%) (HCC/MD) 1 yr-OS (%)
(HCC/MD)
Toxicity
Gr3+ (%)
Mendez-Romero et al. 2006
Phase I/II
25
45
HCC: 11
MD: 34
3.5 (0.5–7.2) 94
(75/100)
82
(75/85)
12.5
Goodman et al.
2010
Phase I
26
40
HCC/CCC: 7
MD: 19
32.6 (0.8–146.6) 77 62 0
Own data 55
70
HCC: 27
MD: 28
6.6 (0.2–204) 91
(92/89)
76
(68/84)
5b
Bujold et al.
2013
Phase I/II
102 HCC only 7.2 (1.4–23.1) 87 55 30
Lasley et al.
2015
Phase I/II
59
59
HCC only 33.6 (2.2–107.3) 91 (Child A)
82 (Child B)
94 (Child A)
57 (Child B)
11 (Child A)
38 (Child B)
Own data 27
36
HCC only 7.5 (0.9–204) 92 68 11b
Scorsetti et al.
2015
Phase I/II
42
52
MD only 3.5 (1.1–5.4) 91 (2 yr) 65 (2 yr) 0
Andratschke et al.
2015
Retro, pooled
74
91
MD only n.r. 75 77 0
Own data 28
34
MD only 6.2 (0.2–98.2) 89 84 0
  1. n: number, LT: liver tumors, GTV: gross tumor volume per lesion, yr.: year, LC: local control, OS: overall survival, HCC: hepatocellular carcinoma, MD: metastatic disease, Gr3+: grade 3+, a in cubic centimeters, b: deterioration of liver function, no other grade 3+ toxicity, n.r.: not reported